Cyclic adenosine-3',5'-monophosphate potentiates the synaptic potential mediated by NMDA receptors in the amygdala
- PMID: 7629888
- DOI: 10.1002/jnr.490400606
Cyclic adenosine-3',5'-monophosphate potentiates the synaptic potential mediated by NMDA receptors in the amygdala
Abstract
An in vitro slice preparation of rat amygdala was used to study the actions of forskolin and cyclic adenosine-3',5'-monophosphate (cAMP) analogues on the N-methyl-D-aspartate (NMDA) receptor-mediated synaptic potential (EPSPNMDA). Intracellular recordings were made from basolateral amygdala neurons in the presence of 6-cyano-7-nitroquinoxaline-2,3-di-one (CNQX, 10 microM) and picrotoxin (50 microM) to pharmacologically isolate the EPSPNMDA. Application of forskolin (25 microM) markedly and persistently potentiated the EPSPNMDA. In contrast, the inactive forskolin analogue, 1,9-dideoxy-forskolin, failed to affect the EPSPNMDA significantly. Superfusion of dibutyryl-cAMP (dbcAMP, 200 microM) for 15 min caused a transient depression of the amplitude of EPSPNMDA. The EPSPNMDA amplitude was reduced to 68 +/- 3% of control (n = 10) 15 min after the application, restored to its control value within 25 min, and followed by a long-term potentiation (LTP). Pretreating the slices with 8-cyclopentyl-1,3-dipropyl-xanthine (DPCPX, 5 microM), a selective A1 receptor antagonist, blocked the transient depressive phase produced by dbcAMP. This result suggests that the transient depression induced by dbcAMP was likely due to the interaction of dbcAMP or its breakdown products with adenosine A1 receptors. To determine the site of action, we examined the effect of forskolin on the postsynaptic responses to exogenously applied NMDA. Forskolin potentiated the postsynaptic depolarization induced by NMDA, suggesting that the enhancement is mediated, at least in part, by a persistent upregulation of postsynaptic NMDA receptor-operated conductances. Occlusion experiments were performed to examine whether the sustained enhancements of EPSP(NMDA) produced by tetanic stimulation (TS) and forskolin share a common mechanism.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Enhancement of NMDA receptor-mediated synaptic potential by isoproterenol is blocked by Rp-adenosine 3',5'-cyclic monophosphothioate.Neurosci Lett. 1993 Oct 29;161(2):207-10. doi: 10.1016/0304-3940(93)90295-v. Neurosci Lett. 1993. PMID: 7903801
-
Long-term enhancement of EPSP and NMDA receptor-mediated synaptic transmission in the amygdala.Brain Res Bull. 1993;31(1-2):7-11. doi: 10.1016/0361-9230(93)90003-t. Brain Res Bull. 1993. PMID: 8095844
-
Pairing of pre- and postsynaptic activities in hippocampal CA1 neurons induces long-term modifications of NMDA receptor-mediated synaptic potential.Brain Res. 1993 Feb 12;603(1):117-20. doi: 10.1016/0006-8993(93)91306-d. Brain Res. 1993. PMID: 8095836
-
Masking of forskolin-induced long-term potentiation by adenosine accumulation in area CA1 of the rat hippocampus.Neuroscience. 1999 Jan;88(1):69-78. doi: 10.1016/s0306-4522(98)00200-0. Neuroscience. 1999. PMID: 10051190
-
Valproic acid suppresses the synaptic response mediated by the NMDA receptors in rat amygdalar slices.Brain Res Bull. 1994;33(3):333-6. doi: 10.1016/0361-9230(94)90202-x. Brain Res Bull. 1994. PMID: 7904890
Cited by
-
The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.Drugs. 1998;55 Suppl 1:1-9. doi: 10.2165/00003495-199855001-00001. Drugs. 1998. PMID: 9483164 Review.
-
Modulation of NMDA receptors in the cerebellum. II. Signaling pathways and physiological modulators regulating NMDA receptor function.Cerebellum. 2005;4(3):162-70. doi: 10.1080/14734220510008003. Cerebellum. 2005. PMID: 16147948 Review.
-
Early Parkinson's disease: what is the best approach to treatment.Drugs Aging. 2000 Sep;17(3):165-81. doi: 10.2165/00002512-200017030-00002. Drugs Aging. 2000. PMID: 11043817 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources